Literature DB >> 15709478

Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta.

Charles C Glabe1.   

Abstract

This chapter reviews recent findings that indicate that soluble amyloid oligomers may represent the primary pathological species in Alzheimer's and other degenerative diseases. Various amyloids share a number of common properties, including their structures and pathways for fibril formation and accumulation in disease. Recent findings suggest that toxic amyloid oligomers share a common structure, suggesting that they also share a common mechanism of pathogenesis

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15709478     DOI： 10.1007/0-387-23226-5_8

Source DB:  PubMed          Journal:  Subcell Biochem        ISSN： 0306-0225


  72 in total

1.  Distinguishing amyloid fibril structures in Alzheimer's disease (AD) by two-dimensional ultraviolet (2DUV) spectroscopy.

Authors:  A R Lam; J Jiang; S Mukamel
Journal:  Biochemistry       Date:  2011-10-20       Impact factor: 3.162

Review 2.  Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease.

Authors:  D Allan Butterfield; Miranda L Bader Lange; Rukhsana Sultana
Journal:  Biochim Biophys Acta       Date:  2010-02-20

3.  Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer's disease and in AβPP transgenic mice using a novel monoclonal antibody.

Authors:  Markus Mandler; Edward Rockenstein; Kiren Ubhi; Lawrence Hansen; Anthony Adame; Sarah Michael; Douglas Galasko; Radmila Santic; Frank Mattner; Eliezer Masliah
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 4.  Nanoimaging for protein misfolding and related diseases.

Authors:  Yuri L Lyubchenko; Simon Sherman; Luda S Shlyakhtenko; Vladimir N Uversky
Journal:  J Cell Biochem       Date:  2006-09-01       Impact factor: 4.429

5.  Recent advances in the development of immunotherapies for tauopathies.

Authors:  Kiren Ubhi; Eliezer Masliah
Journal:  Exp Neurol       Date:  2010-10-21       Impact factor: 5.330

Review 6.  Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies.

Authors:  Aaron M Swomley; Sarah Förster; Jierel T Keeney; Judy Triplett; Zhaoshu Zhang; Rukhsana Sultana; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2013-10-09

7.  Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.

Authors:  John B Rose; Leslie Crews; Edward Rockenstein; Anthony Adame; Michael Mante; Louis B Hersh; Fred H Gage; Brian Spencer; Rewati Potkar; Robert A Marr; Eliezer Masliah
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

8.  In vitro and in vivo degradation of Abeta peptide by peptidases coupled to erythrocytes.

Authors:  Yinxing Liu; Hanjun Guan; Tina L Beckett; Maria Aparecida Juliano; Luiz Juliano; Eun Suk Song; K Martin Chow; M Paul Murphy; Louis B Hersh
Journal:  Peptides       Date:  2007-09-29       Impact factor: 3.750

Review 9.  Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression.

Authors:  D Allan Butterfield; Aaron M Swomley; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2013-02-14       Impact factor: 8.401

Review 10.  Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease.

Authors:  Cassia R Overk; Eliezer Masliah
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.